SLC5A2 and pneumonia: According to the findings presented in another retrospective study, patients with T2DM on SGLT2 inhibitors have a lower incidence of pneumonia and sepsis, as well as a lower mortality risk associated with pneumonia, sepsis, and infectious diseases, in comparison to those initiated on DPP-4 inhibitors, regardless of age, sex, prior CV disease, or type of SGLT2 inhibitor used [49].